At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Tina Vilsbøll discusses the current opinion about cardiorenal risk in patients with T2D.
1. What have recent studies taught us about cardiorenal risk in patients with type 2 diabetes (T2D)? (0:04)
2. How has increased knowledge of cardiorenal risk impacted our management of patients with T2D? (0:52)
3. Should we be increasing the use of sodium-glucose transporter 2 (SGLT2) inhibitor and GLP-1 receptor agonists in patients with T2D with cardiorenal risk? (1:41)
4. What are the advantages and limitations of oral versus injected formulations of semaglutide? (2:48)
5. What are your highlights of EASD so far? (4:23)
Tina Vilsbøll is a Consultant/board for Amgen, Novo Nordisk, MSD, Sun Pharma, Sanofi, Lilly, Boehringer, Mundipharma.
Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.
Share this Video
Related Videos In Diabetes
Andrew Boulton, IDF 2021: Anticipated Congress Highlights
It was a pleasure to meet with IDF President, Prof. Andrew Boulton (University of Manchester, UK) ahead of this year’s virtual meeting to discuss anticipated congress highlights and the relationship between COVID-19 and diabetes. Questions What do you expect to be the highlights of this year’s IDF Congress? (0:20) What have we learned about the […]
IDF Virtual 2021 – Diabetes Complications and Covid-19
The International Diabetes Federation will organise a Virtual Congress on December 6-11, 2021. It will feature the latest research on diabetes complications and sessions dedicated to COVID-19 and diabetes, the centenary of insulin and the IDF Diabetes Atlas 10th Edition. Discover the Congress at https://idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!